Carregant...
Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF(V600E)-Specific Inhibitor)
Malignant melanoma is the most aggressive form of skin cancer and has a very low survival rate. Over 50% of melanomas harbor various BRAF mutations with the most common being the V600E. BRAF(V600E) mutation that causes constitutive activation of the MAPK pathway leading to drug-, immune-resistance,...
Guardat en:
| Publicat a: | Cancers (Basel) |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6025215/ https://ncbi.nlm.nih.gov/pubmed/29795041 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10060157 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|